文献速递胸部肿瘤消化系统肿瘤支持与姑息治疗

2026年美国癌症统计报告

Cancer statistics, 2026.
PubMed 文献 · CA Cancer J Clin · 2026-01-01

美国癌症协会基于截至2022年的发病数据和截至2023年的死亡数据,估算2026年美国将新发约2,114,850例癌症、死亡约626,140例。

要点

  • 2026年美国预计新发癌症2,114,850例,癌症死亡626,140例。
  • 2015-2021年诊断者5年相对生存率总体达70%,远处转移期达35%。

核心结论

  • 数十年科学投入已转化为包括最致命癌症在内患者的更长生存,但联邦癌症研究经费和医保削减可能威胁持续进展。

研究设计与样本

  • 美国癌症协会年度统计报告,发病数据来自中央癌症登记处(截至2022年),死亡数据来自国家卫生统计中心(截至2023年)。

主要发现

  • 2026年美国预计新发癌症2,114,850例、癌症死亡626,140例。
  • 2015-2021年诊断者5年相对生存率总体70%、区域期69%、远处转移期35%,1990年代中期分别为63%、54%、17%。
  • 骨髓瘤5年相对生存率从32%升至62%,肝癌从7%升至22%,转移性黑色素瘤从16%升至35%,转移性直肠癌从8%升至18%,区域期肺癌从20%升至37%,转移性肺癌从2%升至10%。
  • 2026年肺癌所致死亡将超过第二位结直肠癌与第三位胰腺癌之和。

临床怎么用

  • 可引用本报告最新生存率与死亡趋势数据,用于向患者说明总体预后改善及不同分期、瘤种间的差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence and outcomes using data collected by central cancer registries (incidence, through 2022) and the National Center for Health Statistics (mortality, through 2023). In 2026, approximately 2,114,850 new cancer cases and 626,140 cancer deaths are projected to occur in the United States. The cancer mortality rate continued to decline through 2023, averting 4.8 million deaths since 1991, largely because of smoking reductions, earlier detection, and improved treatment. These interventions are also evident in rising 5-year relative survival, which reached a milestone 70% for diagnoses during 2015-2021 overall, 69% for regional-stage disease, and 35% for distant-stage (metastatic) disease, up from 63%, 54%, and 17%, respectively, in the mid-1990s. People with high-mortality cancers and advanced diagnoses had the largest gains, including increases from 32% to 62% for myeloma, 7% to 22% for liver cancer, 16% to 35% for metastatic melanoma, 8% to 18% for metastatic rectal cancer, 20% to 37% for regional lung cancer, and 2% to 10% for metastatic lung cancer. Nevertheless, lung cancer will cause more deaths in 2026 than second-ranking colorectal cancer and third-ranking pancreatic cancer combined. In summary, decades of scientific investment have translated to longer lives for people with even the most fatal cancers. However, continued progress is threatened by proposed federal cuts to cancer research and health insurance, which provides access to life-saving cancer treatment.

来源:CA Cancer J Clin,查看原文。版权归原作者所有。

引用

  1. Siegel RL, Kratzer TB, Wagle NS, et al. Cancer statistics, 2026. CA Cancer J Clin. 2026. PMID: 41528114. doi:10.3322/caac.70043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。